Contact us Demo our platform

LUNCH & LEARN

Advancing Drug Discovery with Metabolomics – Virtual Lunch & Learn

Metabolomics, the study of small molecules called metabolites produced or used by cells in biology, provides powerful data that can accelerate the pursuit of novel discoveries in all areas of life sciences, From disease research, to drug development, nutritional sciences, and environmental sciences, metabolomics provides unique insights, not possible to obtain from other omics, and complimentary insights when combined in a multiomic study.

Join our virtual lunch and learn session hosted by Metabolon, where we delve into the transformative field of metabolomics and its critical role in drug discovery and development. Our experts will provide an introduction to metabolomics, deep dive into the role metabolomics plays in multiomics research, and discuss the utility of this technology through a new case study.

Key takeaways from this webinar:

  • Gain expert knowledge from leaders in the field of metabolomics. 
  • Discover practical applications of metabolomics in drug discovery. 
  • Understand how metabolomics can complement your existing research methodologies. 
  • Enhance your research capabilities with cutting-edge insights.

Program

Time
Presenter
Title/Abstract
10:00 – 10:45 PDT
Dr. Katie Steward, Ph.D.
Introduction to Metabolomics: Dr. Katie Steward from Metabolon will provide an overview of metabolomics, detailing how this field reflects biochemical activity within cells and offers unique insights into a system’s functional status.
Integration with Multiomics Approaches: Understand how metabolomics integrates seamlessly with other omics data (Proteomics, Genomics, etc.), serving as a definitive representation of a phenotype and a key component in systems biology.
Case Study:
Discovery of DRP-104, A Tumor-Targeted Metabolic Inhibitor Prodrug
Explore how metabolomic profiling was instrumental in the development of DRP-104: By analyzing the biochemical changes in tumor cells, researchers identified key metabolic pathways that could be targeted for cancer therapy.
Mechanism of Action: Understand the innovative approach of using tumor-specific proteases to activate DRP-104 within cancer cells, ensuring targeted delivery and reducing toxicity to healthy tissues.
Impactful Results: Delve into the compelling preclinical results showing DRP-104’s effectiveness in inhibiting tumor growth and improving survival rates, especially when used in combination with Anti-PD1 therapy.
Validated by Metabolomics: Discover how global metabolomic profiling validated DRP-104’s targeted action by revealing significant shifts in metabolic pathways, paving the way for new combination therapies and enhancing the overall understanding of tumor biology.
Metabolon’s Expertise: Learn how Metabolon’s advanced metabolomic technologies and comprehensive data analysis capabilities enabled the precise identification of metabolic shifts in tumor cells, leading to the successful design of DRP-104.
Metabolon’s Offerings: Learn about Metabolon’s comprehensive suite of tools and services designed to support metabolomic experiments, providing unparalleled insights for your research needs.

Speakers

K
L

Katie Steward, Ph.D.

Field Metabolomics Scientist at Metabolon

Katie Steward has been working in analytical chemistry for over fifteen years. A mass spectrometry expert, Katie has worked across a variety of application areas, including agriculture, academia, and human health research. Katie’s academic career focused on metabolomics and proteomics to interrogate systemic variability in a myriad of different biological systems. She joined Metabolon in 2022 as a Field Metabolomics Scientist to help bring high-fidelity data to researchers spanning disciplines from drug discovery to crop yield optimization. Marrying the small molecule profile with other omics and analyzing data from a new perspective are what excite Katie the most about metabolomics.

K
L

Sinem Taylor

Business Development Director - San Diego

Sinem Taylor is an enthusiastic sales professional with a strong background in life sciences and genomics. With over 10 years of industry experience, she is passionate about helping researchers and organizations harness the power of metabolomics to advance scientific discoveries.

REGISTER FOR LUNCH & LEARN

Related Webinars

See All Webinars
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.